PMID- 11179474
OWN - NLM
STAT- MEDLINE
DCOM- 20010531
LR  - 20071115
IS  - 1019-6439 (Print)
IS  - 1019-6439 (Linking)
VI  - 18
IP  - 3
DP  - 2001 Mar
TI  - Genetically engineered dendritic cell-based cancer vaccines (review).
PG  - 475-8
AB  - Dendritic cells (DCs) are the most potent professional antigen-presenting cells 
      with exquisite capacity to interact with T cells and initiate their responses; 
      the antigen-presenting capabilities of DCs make them attractive vehicles for the 
      delivery of therapeutic cancer vaccines. The working hypothesis for utilization 
      of DC-based cancer vaccines is that lack of efficient tumour antigen presentation 
      on mature DCs, which is frequently observed in tumour-bearing individuals, can be 
      bypassed by direct loading of DCs with oncoproteins in vitro, thus ensuring the 
      transfer of immunostimulatory peptides on the respective antigen-presenting 
      molecules. To enhance loading of DCs with oncoproteins in vitro and to increase 
      the efficacy of the vaccines, a variety of genetic manipulations have been 
      proposed and shown to be efficient in experimental tumour models. DCs were 
      transfected either with polynucleotides, DNA or RNA, coding for tumour-associated 
      antigens (TAAs), or with DNA encoding immunostimulatory cytokines and 
      co-stimulatory molecules. The delivery of genes coding for antigenic epitopes or 
      other molecules with a recombinant retrovirus, adenovirus, or poxvirus into 
      dendritic cells has also been used for transduction and therapy. As an 
      alternative method for TAA delivery into DCs, fusion of DCs with tumour cells has 
      been utilized and the hybrid cell-based vaccines have been found to be highly 
      therapeutically active, even in cancer patients. The purpose of this review is to 
      summarize the approaches used for making and utilization of the genetically 
      engineered DC-based cancer vaccines, to evaluate the therapeutic results obtained 
      with the vaccines, and to discuss prospects and limitations of the vaccination.
FAU - Bubenik, J
AU  - Bubenik J
AD  - Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, 
      Prague, Czech Republic. bubenik@img.cas.cz
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Greece
TA  - Int J Oncol
JT  - International journal of oncology
JID - 9306042
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (DNA, Viral)
RN  - 0 (Polynucleotides)
SB  - IM
MH  - Animals
MH  - Antigens, Neoplasm/genetics/immunology/metabolism
MH  - Cancer Vaccines/*genetics/immunology
MH  - Clinical Trials as Topic
MH  - DNA, Viral/genetics
MH  - Dendritic Cells/immunology/*physiology
MH  - *Gene Transfer Techniques
MH  - Genetic Engineering/*methods
MH  - Genetic Vectors
MH  - Humans
MH  - Mice
MH  - Neoplasms/therapy
MH  - Polynucleotides/*metabolism
RF  - 45
EDAT- 2001/02/17 11:00
MHDA- 2001/06/02 10:01
CRDT- 2001/02/17 11:00
PHST- 2001/02/17 11:00 [pubmed]
PHST- 2001/06/02 10:01 [medline]
PHST- 2001/02/17 11:00 [entrez]
PST - ppublish
SO  - Int J Oncol. 2001 Mar;18(3):475-8.